Shares of Alembic Prescription drugs Ltd surged greater than 2% on 28 July after the corporate introduced securing last approval from the USFDA for Carbamazepine Prolonged-Launch tablets USP, 100 mg, 200 mg, and 400 mg.
In its inventory market submitting, the corporate declared that “Alembic Prescription drugs has acquired last approval from the US Meals & Drug Administration (USFDA) for its abbreviated new drug utility (ANDA) Carbamazepine extended-release tablets USP, 100 mg, 200 mg, and 400 mg.”
The authorised ANDA is therapeutically much like Novartis Prescription drugs Company’s Tegretol-XR extended-release tablets in strengths of 100 mg, 200 mg, and 400 mg.
Carbamazepine tablets are used as each an anticonvulsant and to alleviate the ache related to real trigeminal neuralgia.
Alembic has acquired 225 ANDA approvals from the USFDA, together with 202 last and 23 tentative clearances.
Moreover, the corporate’s board of administrators will meet on 5 August 2025 to guage and approve unaudited monetary outcomes for the quarter ended 30 June 2025.
Furthermore, Dr. Sachin Ghosalkar has been appointed as Sr. Vice President – SCM & Operations, with impact from 21 July 2025.
At 12:35 pm, the shares of Alembic Pharma have been buying and selling 0.35% greater at Rs 1,001 on NSE.
Uninterested in lacking scorching shares? Unicorn Alerts offers highly effective instruments like inventory scans and extra assist you make knowledgeable buying and selling selections. Obtain now and take management of your portfolio!
